ONC Latest Press Releases

-- October 24, 2026 --

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 Business Wire 4:15 AM

-- October 23, 2026 --

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer Business Wire 10:15 AM

-- October 22, 2026 --

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5 Business Wire 6:01 AM

-- October 19, 2026 --

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026 Business Wire 6:00 AM

-- September 1, 2026 --

BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference Business Wire 6:00 AM

-- August 31, 2026 --

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines Business Wire 3:00 PM

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer Business Wire 6:00 AM

-- August 25, 2026 --

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA Business Wire 10:40 AM

-- August 18, 2026 --

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Business Wire 6:00 AM

-- August 10, 2026 --

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration Business Wire 6:00 AM

-- August 5, 2026 --

BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates Business Wire 6:00 AM

-- July 23, 2026 --

BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines Business Wire 6:00 AM

-- July 17, 2026 --

BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5 Business Wire 6:01 AM

-- June 30, 2026 --

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma Business Wire 6:00 AM

-- June 12, 2026 --

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026 Business Wire 6:00 AM

-- June 11, 2026 --

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit Business Wire 7:24 AM

-- June 1, 2026 --

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026 Business Wire 6:00 AM

-- May 29, 2026 --

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026 Business Wire 6:00 AM

-- May 27, 2026 --

BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026 Business Wire 5:00 PM

-- May 26, 2026 --

BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire 6:01 AM

Market Data Delayed 15 Minutes